JP2006502157A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006502157A5 JP2006502157A5 JP2004533952A JP2004533952A JP2006502157A5 JP 2006502157 A5 JP2006502157 A5 JP 2006502157A5 JP 2004533952 A JP2004533952 A JP 2004533952A JP 2004533952 A JP2004533952 A JP 2004533952A JP 2006502157 A5 JP2006502157 A5 JP 2006502157A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- depression
- independently
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims 17
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 239000002243 precursor Substances 0.000 claims 5
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- -1 cyano, ethyl Chemical group 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000019695 Migraine disease Diseases 0.000 claims 2
- 206010034912 Phobia Diseases 0.000 claims 2
- 206010047163 Vasospasm Diseases 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 2
- 206010027599 migraine Diseases 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 208000031091 Amnestic disease Diseases 0.000 claims 1
- 206010059245 Angiopathy Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000032841 Bulimia Diseases 0.000 claims 1
- 206010006550 Bulimia nervosa Diseases 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010008025 Cerebellar ataxia Diseases 0.000 claims 1
- 206010068631 Childhood depression Diseases 0.000 claims 1
- 208000006561 Cluster Headache Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 1
- 206010019233 Headaches Diseases 0.000 claims 1
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000027089 Parkinsonian disease Diseases 0.000 claims 1
- 206010034010 Parkinsonism Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 206010036618 Premenstrual syndrome Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 1
- 208000000323 Tourette Syndrome Diseases 0.000 claims 1
- 208000016620 Tourette disease Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 230000007000 age related cognitive decline Effects 0.000 claims 1
- 230000006986 amnesia Effects 0.000 claims 1
- 208000022531 anorexia Diseases 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 230000009286 beneficial effect Effects 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000018912 cluster headache syndrome Diseases 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 206010061428 decreased appetite Diseases 0.000 claims 1
- 229960002069 diamorphine Drugs 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000030172 endocrine system disease Diseases 0.000 claims 1
- 230000001667 episodic effect Effects 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 208000024963 hair loss Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 231100000869 headache Toxicity 0.000 claims 1
- 208000031424 hyperprolactinemia Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 125000000814 indol-3-yl group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C([*])C2=C1[H] 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 229960002715 nicotine Drugs 0.000 claims 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 claims 1
- 229960002695 phenobarbital Drugs 0.000 claims 1
- 208000019899 phobic disease Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000001716 specific phobia Diseases 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- FXQMNVHYEDPPPI-UHFFFAOYSA-N 4-[[4-(4-fluorophenyl)piperidin-4-yl]methoxymethyl]-3-methoxynaphthalene-2-carbonitrile Chemical class C12=CC=CC=C2C=C(C#N)C(OC)=C1COCC1(C=2C=CC(F)=CC=2)CCNCC1 FXQMNVHYEDPPPI-UHFFFAOYSA-N 0.000 description 2
- IYLPKSLVPYRHQQ-UHFFFAOYSA-N 4-(iodomethyl)-1,3-dimethoxynaphthalene-2-carbonitrile Chemical compound C1=CC=C2C(OC)=C(C#N)C(OC)=C(CI)C2=C1 IYLPKSLVPYRHQQ-UHFFFAOYSA-N 0.000 description 1
- PQUZDTSQWDVTGK-UHFFFAOYSA-N 4-(iodomethyl)-3-methoxynaphthalene-2-carbonitrile Chemical compound C1=CC=CC2=C(CI)C(OC)=C(C#N)C=C21 PQUZDTSQWDVTGK-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0202674A SE0202674D0 (sv) | 2002-09-09 | 2002-09-09 | Naphthyl ether compounds and their use |
| SE0301052A SE0301052D0 (sv) | 2003-04-08 | 2003-04-08 | Naphthyl ether compounds and their use |
| PCT/SE2003/001399 WO2004022539A1 (en) | 2002-09-09 | 2003-09-08 | Naphthyl ether compounds and their use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006502157A JP2006502157A (ja) | 2006-01-19 |
| JP2006502157A5 true JP2006502157A5 (https=) | 2006-10-19 |
Family
ID=31980726
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004533952A Pending JP2006502157A (ja) | 2002-09-09 | 2003-09-08 | ナフチルエーテル化合物及びそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20050245572A1 (https=) |
| EP (1) | EP1546101A1 (https=) |
| JP (1) | JP2006502157A (https=) |
| AU (1) | AU2003258937A1 (https=) |
| WO (1) | WO2004022539A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7494986B2 (en) * | 2004-07-20 | 2009-02-24 | Bristol-Myers Squibb Company | Cycloalkylamine derivatives as NK-1/SSRI antagonists |
| WO2007003961A2 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| US20070249607A1 (en) | 2006-04-17 | 2007-10-25 | Bristol-Myers Squibb Company | Nk-1 and serotonin transporter inhibitors |
| US8071778B2 (en) | 2006-07-27 | 2011-12-06 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
| WO2008014247A2 (en) * | 2006-07-27 | 2008-01-31 | Bristol-Myers Squibb Company | 4 -arylalkoxymethyl-4- phenyl piperidines and their use as neurokinin receptor antagonists for the treatment of cns disorders |
| US8026257B2 (en) * | 2007-07-11 | 2011-09-27 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
| US20090018163A1 (en) * | 2007-07-11 | 2009-01-15 | Bristol-Myers Squibb Company | Substituted Heterocyclic Ethers and Their Use in CNS Disorders |
| US7632861B2 (en) | 2007-11-13 | 2009-12-15 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in CNS disorders |
| WO2009096941A1 (en) * | 2008-01-28 | 2009-08-06 | Bristol-Myers Squibb Company | Substituted heterocyclic ethers and their use in cns disorders |
| CN105209436B (zh) * | 2013-03-15 | 2019-02-01 | 南洋理工大学 | 3-哌啶酮化合物及其作为神经激肽-1(nk1)受体拮抗剂的用途 |
| CN108530262A (zh) * | 2018-06-15 | 2018-09-14 | 贾红琴 | 一种2-溴芴的合成方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU678409B2 (en) * | 1992-10-28 | 1997-05-29 | Merck Sharp & Dohme Limited | 4-arylmethyloxymethyl piperidines as tachykinin antagonists |
| ATE170174T1 (de) * | 1994-01-13 | 1998-09-15 | Merck Sharp & Dohme | Gem-bissubstituierte azazyclische tachykinin- antagonisten |
| US5491140A (en) * | 1994-06-30 | 1996-02-13 | Eli Lilly And Company | Naphthyl tachykinin receptor antagonists to treat physiological conditions |
| GB9904786D0 (en) * | 1999-03-02 | 1999-04-28 | Merck Sharp & Dohme | Therapeutic agents |
| WO2004020411A1 (en) * | 2002-08-29 | 2004-03-11 | Astrazeneca Ab | Naphthamide derivatives and their use |
| ES2286470T3 (es) * | 2002-12-20 | 2007-12-01 | Astrazeneca Ab | Compuestos de 4-aril-4-(naft-1-ilmetilamino)metil-piperidina y su uso. |
-
2003
- 2003-09-08 WO PCT/SE2003/001399 patent/WO2004022539A1/en not_active Ceased
- 2003-09-08 EP EP03794408A patent/EP1546101A1/en not_active Withdrawn
- 2003-09-08 JP JP2004533952A patent/JP2006502157A/ja active Pending
- 2003-09-08 AU AU2003258937A patent/AU2003258937A1/en not_active Abandoned
- 2003-09-08 US US10/527,280 patent/US20050245572A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001283955B2 (en) | Piperazine derivatives | |
| AU2015242330B2 (en) | Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators | |
| CN106458914B (zh) | 作为axl抑制剂的杂环化合物 | |
| JP2006502157A5 (https=) | ||
| TW200732339A (en) | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | |
| JP2019519583A (ja) | 神経性疾患および神経変性疾患を処置するための５，７−ジヒドロピロロピリジン誘導体 | |
| TW201024301A (en) | Amino pyrazole compound | |
| CA2651363A1 (en) | Triazolopyrazine derivatives useful as anti-cancer agents | |
| BR122023004130B1 (pt) | Compostos heteroaromáticos, composição farmacêutica e uso dos referidos compostos no tratamento de distúrbios mediados ou associados a dopamina d1 | |
| HK1217945A1 (zh) | 作爲pde4亚型抑制剂用於治疗cns和其他病症的氮杂苯并咪唑化合物 | |
| CY1112418T1 (el) | Παραγωγα σουλφονυλοπυραζολινο-1-καρβοξαμιδινης ως 5-ητ6 ανταγωνιστες | |
| NZ580801A (en) | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | |
| CN1926140A (zh) | 吡咯并嘧啶衍生物 | |
| CN103717593A (zh) | 调节激酶的组合物和方法 | |
| NZ580802A (en) | Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin | |
| JP2007520539A5 (https=) | ||
| JP2016531880A (ja) | ガンマセクレターゼモジュレーターとしての新規二環式ピリジノン | |
| HK1042649A1 (zh) | 嘧啶衍生物在预防和治疗脑缺血中的应用 | |
| ATE432930T1 (de) | Benzosulfonamide derivate, deren verfahren zum herstellung, und deren verwendung zur behandlung von schmerzen | |
| UA93687C2 (en) | N-(heteroaryl)-1-heteroarylalkyl-1h-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | |
| MX2007015678A (es) | Antagonistas y agonistas de piperazina-piperidina del receptor 5-ht-1a. | |
| TW200808741A (en) | 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts | |
| TWI283679B (en) | 7-phenylpyrazolopyridine compounds | |
| JP2006502239A5 (https=) | ||
| JP2007523207A5 (https=) |